Andrea Millsap Joins Vivera Pharmaceuticals As National Sales DirectorHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Andrea Millsap Joins Vivera Pharmaceuticals As National Sales DirectorNewsfile Corp.NewsfileJanuary 7, 2020ReblogShareTweetShareNewport Beach, California--(Newsfile Corp. - January 7, 2020) -  Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces the appointment of Andrea Millsap as the Company's National Sales Director. A key aspect of her role is to develop and implement sales strategies and infrastructure for Vivera's entire sales team."I am thrilled to join Vivera to help increase awareness of its innovative products," said Ms. Millsap. "I look forward to using my expertise to forge strong relationships with customers and physicians across the country. I began my career within the pharmaceutical industry because of my desire to help people and I believe that Vivera's TVIA Kit® products can change the landscape when it comes to pain management."A highly skilled sales and marketing executive, Ms. Millsap previously held positions at Pfizer Pharmaceuticals, Zila Pharmaceuticals, and Nevada Dental Associates prior to joining Vivera. At Pfizer for over eight years, Ms. Millsap was the District Product Lead for Lyrica and instrumental in the Eucrisa product launch. Appointed Lyrica Field Force Faculty, she aided in the roll out and implementation of the Lyrica brand strategy. Other responsibilities at Pfizer included promoting its product portfolio to high volume primary care offices and specialty offices to increase provider and patient awareness. An ambitious leader, Ms. Millsap was able to quickly establish rapport, build credibility and cultivate lasting relationships with major accounts during her time at both Pfizer and Zila."I am confident that Andrea will excel in her new role with us," said Paul Edalat, Chairman and Founder of Vivera. "She is an outstanding motivator with a proven track record of developing high-performing sales teams and creating a winning culture. Plus, she brings a unique perspective that I believe will better serve our sales force, and ultimately our customers.""Not only have I had a successful career in pharmaceutical sales, but I recently had heart surgery and when I left the hospital, I used Vivera's products," added Ms. Millsap. "I'm living proof that the products work and I'm eager to share my experience and help Vivera make a difference. I'm excited for what the future holds."Ms. Millsap received a Bachelor of Arts degree in Corporate Communications from the University of Nevada, Las Vegas and is a part of the Alumni Association. She was a Member of the Primary Care Performance Pillar Team in 2016. In 2016 she was also selected by her peers for the Pfizer "Own It" award, an award given for demonstrating excellence within the field and amongst fellow cohorts. Ms. Millsap was a 2015 Summit Winner, finishing the year as one of the top 10 national sales representatives in the country. She is passionate about patient advocacy and making a difference in the healthcare sector.About Vivera Pharmaceuticals, Inc. Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT™ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT™ drug delivery format with the goal of gaining FDA approval for its products.The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.For more information, visit https://viverapharmaceuticals.com.Investor Relations Inquiries:thinkHEROPatrick Piette, CFA for Vivera Pharmaceuticals, Inc.416-526-9911investorrelations@viverapharma.comPress Inquiries:thinkHEROKarin Elz, for Vivera Pharmaceuticals, Inc.416-992-9848press@viverapharma.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/51215ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextUS gives Iran sanctions waiver for humanitarian tradeThe IndependentMylan warns of possible drug shortages, financial hit due to coronavirusReutersPfizer warns of hit to financial results on continued coronavirus outbreakReutersOpioid companies say lawyers' fee demand threatens settlement talksReutersBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoAsian markets continue to slump, as Nikkei enters correction territoryMarketWatch'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDelfi Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next YearSimply Wall St.